Share prices of Moderna (NASDAQ: MRNA) plummeted 58% in 2024, ranking among the worst performers in the S&P 500 index. The ...

It was an extremely busy week in the biotech sector, with several companies making important presentations at the J.P. Morgan ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...

Annemarie Hanekamp has overseen some of the most transformative changes in oncology over her years in Big Pharma. Now, she ...

Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but ...

Moderna is down 80% from its 52-week high as revenues continue to fall and the new RSV vaccine has performed poorly. Read my ...

Is Moderna a no-brainer buy on the sell-off? I wouldn't go that far. Investors should think long and hard about the company's ...

Analyst Mani Foroohar of Leerink Partners maintained a Sell rating on Moderna (MRNA – Research Report), reducing the price target to ...

Combining human efforts, nature, and AI in what Noubar Afeyan calls “polyintelligence” could solve problems such as climate ...

Biopharma executives were busy Monday, striking high-value deals and providing updates on cancer, obesity and vaccine ...

Moderna's mRNA technology gained rapid validation as sales of its covid vaccine soared in 2021 and 2022, but we think the firm has yet to secure a narrow economic moat around its business, largely due ...

Shares of Moderna plunged 20% Monday after the vaccine maker slashed its forecast of full-year 2025 revenue, as sales of its ...